Key result
Huatan Jiangzhuo decoction suppresses lipid accumulation and dyslipidemia in hyperlipidemic rats by reversing mRNA expression.
Why the study?
Chinese medicine offers a potential lipid-lowering approach with high efficiency and low toxicity for hyperlipidemia, but its molecular mechanisms remain unclear.
Population
Rats with hyperlipidemia
Comparison
Huatan Jiangzhuo decoction vs untreated hyperlipidemic model group
Design
Network pharmacology, RNA sequencing, and animal experiment
Authors
Loading...
Preclinical data support further HTJZD development for hyperlipidemia; leaves open translation to human efficacy and safety.
p-value: p=<0.01
Network pharmacology and animal experiments suggest Huatan Jiangzhuo decoction improves hyperlipidemia by regulating lipid metabolism and insulin resistance pathways.
Zhou et al. (2021) studied Hyperlipidemia. Huatan Jiangzhuo decoction (HTJZD) vs. Model group was evaluated on Srebp-1c, Cyp3a9, and Insr mRNA expression (p=<0.01). Huatan Jiangzhuo decoction effectively reversed Srebp-1c, Cyp3a9, and Insr mRNA expression in rats with hyperlipidemia (P < 0.01), suppressing lipid accumulation and dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: